dr. goy discusses long-term follow-up results for ibrutinib in mcl
Published 6 years ago • 111 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
1:25
dr. goy discusses single-agent ibrutinib in mcl
-
1:51
long-term results of ibrutinib/umbralisib show efficacy in cll and mcl
-
0:53
andre goy, md, discusses the best strategy for using ibrutinib in mcl
-
0:46
dr. goy discusses potential for combination therapy in mcl
-
1:09
dr. goy discusses ibrutinib with venetoclax in mcl
-
1:36
dr. rule on long-term follow-up of ibrutinib monotherapy in relapsed/refractory mcl
-
0:46
dr. goy compares acalabrutinib with ibrutinib in mcl
-
0:47
venetoclax plus ibrutinib combo shows potential in relapsed/refractory mcl
-
1:06
dr. goy on efficacy with ibrutinib in mcl
-
1:27
real-world data for ibrutinib in relapsed/refractory mcl
-
1:33
btk inhibitors improve responses relapsed/refractory mantle cell lymphoma
-
2:07
dr. goy discusses intensive therapy for mcl
-
2:00
dr. goy discusses btk inhibitors in mcl
-
3:42
acalabrutinib monotherapy in r/r mcl: extended follow-up results
-
1:48
goy predicts strategies for the future of mcl treatment
-
1:15
dr. goy on treatment considerations in mcl
-
0:48
real-world results in the uk for ibrutinib at first relapsed for mcl
-
1:24
dr. goy on preliminary data with ibrutinib/venetoclax in relapsed/refractory mcl
-
1:28
dr. goy on the evolution of treatment selection in mcl